Caris Life Sciences, Inc.
32.00USD
+0.2900 (+0.91%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on CAI.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 264 | 216 | 293 | 217 | 181 | 121 | 130 | 102 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | 27 | 5 | 88 | 33 | -18 | -58 | -37 | -61 |
| Net Income | -1 | -1 | 82 | 24 | -72 | -103 | -37 | -68 |
| EPS (Diluted) | $0.00 | $0.00 | $1.61 | $0.08 | -$7.97 | -$3.57 | -$1.74 | -$2.59 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)